蜈蚣提取液的分离纯化与治疗肝细胞性肝癌机制的研究
|
摘要
肝细胞性肝癌(hepatocellular carcinoma, HCC)是全世界最常见的恶性肿瘤之一,死亡率在癌症中占第三位,在亚洲和非洲平均每年100,000人中就有约50-150人死于HCC。近20年来,我国HCC的治疗尽管取得了长足的进步,早期诊断率、手术切除率、术后生存率及生存质量均有较大提高,但HCC的发病率和死亡率仍占癌症中的第二位。
治疗方法选择主要取决于肿瘤的分期及肝功能情况。手术切除(包括部分肝切除和肝移植)可能治愈小肝癌,而对进展期和转移性HCC疗效有限。对于不能手术切除或全身情况差不能耐受手术者,可采取肿瘤的局部和全身治疗相结合的方法。尽管目前治疗方法很多,但每种方法各有其局限性,对中、晚期HCC的疗效有限。故寻找有效的治疗药物是提高中、晚期HCC存活率及改善生活质量的重要手段,具有重要意义。
在我国,蜈蚣用于疾病的预防和治疗已有两千余年的历史。近年研究表明蜈蚣全虫提取液有多种作用,其抗肿瘤的效果亦有少量报道。为此,我们以肝癌细胞株Bel-7402为研究对象,采用分离纯化的蜈蚣提取液产物处理细胞,通过观察其对Bel-7402细胞的增殖及形态等的影响,进一步了解蜈蚣提取液治疗肝癌的效果并探讨其作用机制,为蜈蚣提取液临床治疗肝癌提供理论基础。
第一章蜈蚣蛋白质体外抗癌作用的研究
目的：提取ECP总液并将其分离为上清液和蛋白质,分别研究三者对肝癌细胞株Bel-7402增殖的抑制作用。
方法：体外培养肝癌细胞株Bel-7402,分别采用不同浓度ECP总液、上清液及蛋白质处理细胞,利用倒置光学显微镜观察Bel-7402细胞的形态变化,并通过MTT法研究肝癌细胞Bel-7402对它们的敏感性。同时体外培养正常肝细胞株L02,观察不同浓度ECP总液处理后,L02细胞形态学改变及对ECP总液的敏感性。
结果：
①光镜下和细胞计数结果示,ECP总液、ECP蛋白质和5-Fu作用48小时后,Bel-7402细胞数量减少明显,部分未坏死细胞形态变圆变小,而ECP上清液作用Bel-7402细胞、ECP总液作用L02细胞48小时后,表现为细胞数量减少不明显。
②MTT法示,ECP总液、ECP蛋白质和5-Fu对Bel-7402细胞的抑制率分别为0.788、0.453、0.944,而ECP上清液对Bel-7402细胞的抑制率为0.198,ECP总液对L02细胞的抑制率为0.095。
③MTT法示ECP总液在12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml、0.0012mg/ml时,对肝癌细胞株Bel-7402的抑制率分别为0.788、0.608、0.308、0.207、0.099,其半数抑制浓度(IC50)为9.597mg/ml。ECP蛋白质在2.9mg/ml、0.29mg/ml、0.029mg/ml、0.0029mg/ml、0.00029mg/ml时,对肝癌细胞株Bel-7402的抑制率分别为0.453、0.208、0.145、0.077、0.063, IC50为1.372mg/ml。
④细胞生长-抑制率曲线示对Bel-7402细胞抑制率,随ECP总液和ECP蛋白质的浓度的增加而依次提高,与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。
⑤MTT法示ECP总液在12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml、0.0012mg/ml时,对肝细胞株L02的抑制率分别为0.095、0.040、0.037、0.022、0.005。
结论：
①ECP总液中抑制肝癌细胞株Bel-7402生长的主要是ECP中的蛋白质成分,ECP总液和ECP蛋白质能抑制Bel-7402细胞的增殖,且抑制作用呈剂量依赖效应；ECP上清液对肝癌细胞株Bel-7402的增殖没有明显影响。
②ECP总液对肝细胞株L02的增殖没有明显影响。
第二章蜈蚣蛋白质抗肿瘤活性成分的分离纯化
目的：逐层分离纯化蜈蚣总蛋白质,观察肝癌细胞株Bel-7402对所得产物的敏感性并进行有效成分鉴定。
方法：①体外培养肝癌细胞株Bel-7402,采用Bestarose Cross Link-6B (CL-6B)凝胶过滤、DEAE Sepharose FF离子交换层析、Sephadex G-75凝胶过滤对ECP蛋白质进行分离纯化；将得到的产物分别以不同浓度干预Bel-7402细胞,采用MTT法进行体外抑瘤活性检测；②利用倒置光学显微镜,观察经不同浓度ECP蛋白质的分离物处理后Bel-7402细胞形态的变化,以找出蜈蚣主要抗肿瘤活性蛋白质；③通过SDS-PAGE电泳对有效成分进行分子量测定。
结果：①ECP蛋白质经过CL-6B凝胶过滤层析后,得到5种成分。光镜下、细胞计数和MTT法示,C、E液抑制Bel-7402细胞生长明显,其所含蛋白质分子量范围分别在1.6X106～2.2X106、1X104～4X105。MTT法和细胞生长-抑制率曲线图示,对Bel-7402细胞抑制率随C、E液的浓度的增加而依次提高。与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。
②将C、E液合并通过DEAE Sepharose FF离子交换层析后,得到7种成分,光镜下、细胞计数和MTT法示G、I液抑制Bel-7402细胞生长明显,其所含蛋白质等电点在6.8以下。MTT法和细胞生长-抑制率曲线图示,对Bel-7402细胞抑制率随G、I液的浓度的增加而依次提高。与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。
③将G、I液合并通过Sephadex G-75凝胶过滤层析后,得到4种成分,光镜下、细胞计数和MTT法示,O、P液抑制Bel-7402细胞生长明显,其所含蛋白质分子量范围分别在4×104～6×104、2×104～4×104。MTT法和细胞生长-抑制率曲线图示,对Bel-7402细胞抑制率随O、P液的浓度的增加而依次提高。与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。O液的IC50为1.132mg/ml, P液的IC50为1,129 mg/ml。
④SDS-PAGE电泳结果示,O、P液含多种蛋白质,其中O液包括7条含量较高的蛋白质,其分子量分别在120kD (1kD=103),60 kD,48 kD,35 kD,33 kD,25 kD,20 kD左右。P液中存在6条含量较高的蛋白质,其分子量分别在120kD,80 kD,35 kD,33 kD,25 kD,20 kD左右。
⑤光镜下、细胞计数和MTT法示不同浓度的A、B、D、H、J、K、L、M、N液对肝癌细胞株Bel-7402的生长抑制作用不明显。
结论：
①经CL-6B、DEAE FF、Sephadex G-75得到的抗肿瘤活性成分,两者均为酸性蛋白质混合物,其分子量范围在2×104-6×104之间；
②O液和P液均能抑制Bel-7402细胞的增殖,其作用呈剂量依赖性,O、P液体外抑瘤活性较ECP总液均提高了约8.5倍；
第三章ECP总液对肝癌细胞株Bel-7402的作用及机制的研究
目的：研究ECP总液对肝癌细胞株Bel-7402中Galectin-7和p-JNK1表达的影响,并进一步探讨其作用机制。
方法：以半数抑制浓度的ECP总液(1Omg/ml)诱导肝癌细胞株Bel-7402不同时间(0h、3h、6h、12h、24h、48h),通过Western blot、Real time-PCR、免疫荧光检测细胞内Galectin-7和p-JNK1的蛋白及mRNA表达；用Galectin-7-siRNA预处理Bel-7402细胞,再予lOmg/ml ECP总液诱导48 h,观察Galectin-7的蛋白及mRNA表达和p-JNK1的蛋白表达变化。
结果：①Western blot、Real time-PCR、免疫荧光均显示,ECP总液干预呈时间依赖性上调肝癌细胞株Bel-7402中Galectin-7和p-JNK1的蛋白及mRNA,与对照组相比差异有统计学意义(P<0.01)。
②Western blot、Real time-PCR、免疫荧光均显示,Galectin-7-siRNAs可显著抑制ECP总液对Galectin-7的蛋白及mRNA表达的诱导作用,与ECP总液刺激组相比差异有统计学意义(P<0.05)。
③Western blot显示,Galectin-7-siRNAs可显著抑制ECP总液对p-JNK1蛋白表达的诱导作用,与ECP总液刺激组相比差异有统计学意义(P<0.05),与对照组相比差异有统计学意义(P<0.05)。
结论：
ECP总液呈时间依赖性上调肝癌细胞株Bel-7402中Galectin-7的蛋白及mRNA和p-JNK1的蛋白及mRNA,提示ECP总液可能通过Galectin-7-JNK途径促进肝癌细胞株Bel-7402的凋亡。
Hepatocellular carcinoma (HCC) was one of the most common malignancy tumor in worldwide. It was the third leading cause of death attributable to cancer. The incidence of 50-150 HCC cases per 100,000 population and year in parts of Africa and Asia where HCC was responsible for a large proportion of cancer deaths. In recent 20 years, despite the emergence of various therapeutic modalities such as diagnosis at an early stage, hepatic resection and radiofrequency ablation were therapy and chemotherapy. In China, HCC was the second the incidence of and mortality of cancer.
The treatment for the patient mainly depended on the stage of the tumor and the liver function. As we all known, although surgery (partial hepatectomy or total hepatectomy with orthotopic liver transplantation) could be curative for localized small liver tumors, therapeutic options for patients with advanced or metastatic HCC were limited. The patients who had no chance to undergo hepatic resection or could not bear the surgery may be cured by combination of region treatment with integration treatment. There were many methods for it, But all treatments had their own respective limitations; and the therapeutic effect for the patients with advanced stage of HCC was still poor. Further elucidation of the molecular pathogenesis of HCC and exploration of an effective drug may facilitate the development of more effective therapeutic interventions for HCC.
Centipede as a drug applied to prophylaxis and treatment of diseases had a history of more than two thousand years. The extract of whole centipede was proved to have many effects in disease treatment in recent years. But the reports about its effect in carcinomas' treatment were in odds and ends, and the method for experiment of tumor therapy only limits to MTT. Up to now, little information of its detailed mechanism of action had been known to us. In order to investigate the sensibility and mechanisms of HCC cell to extract of centipede (ECP),we took HCC Bel-7402 cell line and model of heterotopic grafting carcinoma for HCC Bel-7402 to research treatment with ECP by a series of methods.What we did aim to give its theory to clinic treatment with ECP for HCC.
ChapterⅠAssay sensibility of HCC Bel-7402 cell line to ECP in vitro
Objective:To investigate the inhibitory effect of ECP, supernatant and protein from ECP on human HCC Bel-7402 cell line.
Method: Bel-7402 cell line were cultured in vitro; ECP、the supernatant from ECP and its protein were applied to the interference of the growth of Bel-7402 with different drug concentration; MTT method and cell amounts were employed to investigate the sensibility to them. We observe cell morpheus changes through inversion light microscope. LO2 cell line was cultured in vitro. ECP were applied to the interference of the growth of LO2 with different drug concentration; MTT method and cell amounts were employed to investigate the sensibility to them.
Result:①According to light microscope and cell amounts after 48 hours, we found out that these were viable counts of Bel-7402 decrease at the ECP、the protein of ECP and 5-Fu, no evident depressant effect for cells Bel-7402 at the supernatant from ECP and for cells LO2 at the ECP.
②The result of MTT method showed that the inhibition ratio to Bel-7402 of ECP、the protein of ECP、the supernatant from ECP and 5-Fu was 0.788、0.453、0.198 and 0.944, respectively. The inhibition ratio to LO2of ECP was 0.095.
③The result of MTT method showed that the inhibition ratio of various concentration of ECP at 12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml and 0.0012mg/ml was 0.788、0.608、0.308、0.207 and 0.099, respectively, and IC50 of ECP to Bel-7402 was 9.597mg/ml. The inhibition ratio of various concentration at 2.9mg/ml、0.29mg/ml、.029mg/ml、.0029mg/ml and 0.00029mg/ml was 0.453、0.208、0.145、0.077 and 0.063, respectively, and IC50 to Bel-7402 was 1.372mg/ml.
④Drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with ECP and the protein of ECP concentration. There existed distinct discrepancies for different groups (P<0.05)
⑤The result of MTT method showed that the inhibition ratio of various concentration of ECP at 12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml and 0.0012mg/ml was 0.095、0.040、0.037、0.022 and 0.005, respectively.
Conclusion:
①ECP and the protein of ECP could inhibit the growth of Bel-7402 cells. The inhibitory effect was concentration dependent. The supernatant from ECP had no transparent inhibiting on Bel-7402.
②ECP had no transparent inhibition on LO2.
ChapterⅡIsolation, Purification the anti-tumor protein extracted from ECP
Objective:To investigate the sensibility of HCC Bel-7402 cell line by treatment of the protein of ECP was isolated and purified by gel filtration, ion-exchange chromatography. The molecular weights of proteins were identified by SDS-PAGE electrophoresis method.
Method:①Bel-7402 cell line were cultured in vitro. The protein of ECP was isolated and purified by gel filtration on CL-6B, DEAE-Sepharose-FF anion-exchange chromatography and gel filtration on Sephadex G-75, applied to the interference of the growth of Bel-7402 with different drug concentration; MTT method and cell amounts were employed to investigate the sensibility to them.
②We observe cell morpheus changes through inversion light microscope.
③The molecular weights of effective components were identified by SDS-PAGE.
Result:①A、B、C、D、E were separated from the protein of ECP by gel filtration on CL-6B column. According to light microscope、the cell amounts and MTT after 48 hours, we found out that the proteins compound C and E had remarkable suppressive on the proliferation of Bel-7402 in vitro. The protein molecular weights of C and E were mainly distributed between 1.6×106～2.2X 106、1×104～4×105, respectively. The result of MTT method and drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with C and E concentration. The cell proliferation was slower than that of contrast group (P＜0.05)
②F、G、H、I、J、K、L were separated from the compound C and E by DEAE-Sepharose-FF anion-exchange chromatography. According to light microscope、the cell amounts and MTT after 48 hours, we found out that the proteins compound G and I had remarkable suppressive on the proliferation of Bel-7402 in vitro. The pI of G and I less than 6.8. The result of MTT method and drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with G and I concentration. The cell proliferation was slower than that of contrast group (P＜0.05)
③M、N、O、P were separated from the compound G and I by gel filtration on Sephadex G-75 column. T According to light microscope、the cell amounts and MTT after 48 hours, we found out that the proteins compound O and P had remarkable suppressive on the proliferation of Bel-7402 in vitro. The protein molecular weights of O and P were mainly distributed between 4×104～6×104、2×104～4×104 respectively. he result of MTT method and drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with G and I concentration. The cell proliferation was slower than that of contrast group (P<0.05).IC50 of O and P to Bel-7402 was 1.132mg/ml and 1.129mg/ml, respectively.
④In SDS-PAGE,7 major bands were showed in O (molecular weights: 120Kd(1=103),60 kD,48 kD,35 kD,33 kD,25 kD,20 kD.6 major bands were showed in P (molecular weights: 120kD,80 kD,35 kD,33 kD,25 kD,20 kD).
⑤A、B、D、F、H、J、L、M、N from ECP could inhibit the growth of HCC Bel-7402 cell line at different concentration, but the growth inhibiting rate were low.
Conclusion:
①O、P were separated from the protein of ECP by gel filtration on CL-6B column、DEAE-Sepharose-FF anion-exchange chromatography、gel filtration on Sephadex G-75 column, which were compound of acidic protein. The protein molecular weights of O and P were mainly distributed between 2×104～6×104.
②O、P could inhibit the growth of the Bel-7402. The inhibitory effect was concentration dependent. And its suppressive effect on the proliferation of Bel-7402 was nearly 8.5 times more than the crude proteins of ECP.
ChapterⅢTo explore the mechanisms in human Bel-7402 cell line treated with ECP
Objective: To explore the effect of antitumor molecular mechanisms, the HCC Bel-7402 cell line were treated with ECP.
Method:Bel-7402 cells line were treated with ECP (10mg/ml) in different time (0、3、6、12、24、48h). The expression of Galectin-7 and p-JNK1 protein expression and mRNA were examined by Western Blot, Real Time-PCR and immunofluo-rescence staining. We treated Bel-7402 cells line with Galectin-7-siRNA, then Bel-7402 cells line were treated with ECP (10mg/ml) in 48h. The expression of Galectin-7 protein expression and mRNA, and p-JNK1 protein expression were examined by Western Blot, Real Time-PCR and immunofluorescence staining.
Result:
①Western Blot, Real Time-PCR and Immunofluorescence staining showed that expression of Galectin-7, p-JNK1 protein and mRNA were up regulated in a time-dependent manner in Bel-7402 stimulated with ECP. There was significantly difference among ECP groups and contrast group (P<0.01)
②Western Blot, Real Time-PCR and Immunofluorescence staining showed that expression of Galectin-7, p-JNK1 protein and mRNA were decreased in Bel-7402 stimulated with ECP in the presence of Galectin-7-siRNAs compared with Bel-7402 stimulated with ECP (P<0.05)
③Western blot showed that induction of p-JNK1 protein was decreased in Bel-7402 stimulated with ECP in the presence of Galectin-7-siRNAs compared with Bel-7402 stimulated with ECP (P<0.05). There was significantly difference amongs Galectin-7-siRNAs groups and contrast group (P<0.05)
Conclusion:
Galectin-7, p-JNK1 protein and mRNA were up regulated in a time-dependent manner in Bel-7402 stimulated with ECP. ECP maybe activate Galectin-7-JNK pathway to induce apoptosis of Bel-7402.
治疗方法选择主要取决于肿瘤的分期及肝功能情况。手术切除(包括部分肝切除和肝移植)可能治愈小肝癌,而对进展期和转移性HCC疗效有限。对于不能手术切除或全身情况差不能耐受手术者,可采取肿瘤的局部和全身治疗相结合的方法。尽管目前治疗方法很多,但每种方法各有其局限性,对中、晚期HCC的疗效有限。故寻找有效的治疗药物是提高中、晚期HCC存活率及改善生活质量的重要手段,具有重要意义。
在我国,蜈蚣用于疾病的预防和治疗已有两千余年的历史。近年研究表明蜈蚣全虫提取液有多种作用,其抗肿瘤的效果亦有少量报道。为此,我们以肝癌细胞株Bel-7402为研究对象,采用分离纯化的蜈蚣提取液产物处理细胞,通过观察其对Bel-7402细胞的增殖及形态等的影响,进一步了解蜈蚣提取液治疗肝癌的效果并探讨其作用机制,为蜈蚣提取液临床治疗肝癌提供理论基础。
第一章蜈蚣蛋白质体外抗癌作用的研究
目的：提取ECP总液并将其分离为上清液和蛋白质,分别研究三者对肝癌细胞株Bel-7402增殖的抑制作用。
方法：体外培养肝癌细胞株Bel-7402,分别采用不同浓度ECP总液、上清液及蛋白质处理细胞,利用倒置光学显微镜观察Bel-7402细胞的形态变化,并通过MTT法研究肝癌细胞Bel-7402对它们的敏感性。同时体外培养正常肝细胞株L02,观察不同浓度ECP总液处理后,L02细胞形态学改变及对ECP总液的敏感性。
结果：
①光镜下和细胞计数结果示,ECP总液、ECP蛋白质和5-Fu作用48小时后,Bel-7402细胞数量减少明显,部分未坏死细胞形态变圆变小,而ECP上清液作用Bel-7402细胞、ECP总液作用L02细胞48小时后,表现为细胞数量减少不明显。
②MTT法示,ECP总液、ECP蛋白质和5-Fu对Bel-7402细胞的抑制率分别为0.788、0.453、0.944,而ECP上清液对Bel-7402细胞的抑制率为0.198,ECP总液对L02细胞的抑制率为0.095。
③MTT法示ECP总液在12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml、0.0012mg/ml时,对肝癌细胞株Bel-7402的抑制率分别为0.788、0.608、0.308、0.207、0.099,其半数抑制浓度(IC50)为9.597mg/ml。ECP蛋白质在2.9mg/ml、0.29mg/ml、0.029mg/ml、0.0029mg/ml、0.00029mg/ml时,对肝癌细胞株Bel-7402的抑制率分别为0.453、0.208、0.145、0.077、0.063, IC50为1.372mg/ml。
④细胞生长-抑制率曲线示对Bel-7402细胞抑制率,随ECP总液和ECP蛋白质的浓度的增加而依次提高,与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。
⑤MTT法示ECP总液在12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml、0.0012mg/ml时,对肝细胞株L02的抑制率分别为0.095、0.040、0.037、0.022、0.005。
结论：
①ECP总液中抑制肝癌细胞株Bel-7402生长的主要是ECP中的蛋白质成分,ECP总液和ECP蛋白质能抑制Bel-7402细胞的增殖,且抑制作用呈剂量依赖效应；ECP上清液对肝癌细胞株Bel-7402的增殖没有明显影响。
②ECP总液对肝细胞株L02的增殖没有明显影响。
第二章蜈蚣蛋白质抗肿瘤活性成分的分离纯化
目的：逐层分离纯化蜈蚣总蛋白质,观察肝癌细胞株Bel-7402对所得产物的敏感性并进行有效成分鉴定。
方法：①体外培养肝癌细胞株Bel-7402,采用Bestarose Cross Link-6B (CL-6B)凝胶过滤、DEAE Sepharose FF离子交换层析、Sephadex G-75凝胶过滤对ECP蛋白质进行分离纯化；将得到的产物分别以不同浓度干预Bel-7402细胞,采用MTT法进行体外抑瘤活性检测；②利用倒置光学显微镜,观察经不同浓度ECP蛋白质的分离物处理后Bel-7402细胞形态的变化,以找出蜈蚣主要抗肿瘤活性蛋白质；③通过SDS-PAGE电泳对有效成分进行分子量测定。
结果：①ECP蛋白质经过CL-6B凝胶过滤层析后,得到5种成分。光镜下、细胞计数和MTT法示,C、E液抑制Bel-7402细胞生长明显,其所含蛋白质分子量范围分别在1.6X106～2.2X106、1X104～4X105。MTT法和细胞生长-抑制率曲线图示,对Bel-7402细胞抑制率随C、E液的浓度的增加而依次提高。与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。
②将C、E液合并通过DEAE Sepharose FF离子交换层析后,得到7种成分,光镜下、细胞计数和MTT法示G、I液抑制Bel-7402细胞生长明显,其所含蛋白质等电点在6.8以下。MTT法和细胞生长-抑制率曲线图示,对Bel-7402细胞抑制率随G、I液的浓度的增加而依次提高。与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。
③将G、I液合并通过Sephadex G-75凝胶过滤层析后,得到4种成分,光镜下、细胞计数和MTT法示,O、P液抑制Bel-7402细胞生长明显,其所含蛋白质分子量范围分别在4×104～6×104、2×104～4×104。MTT法和细胞生长-抑制率曲线图示,对Bel-7402细胞抑制率随O、P液的浓度的增加而依次提高。与Bel-7402阴性对照组比较差异有统计学意义(P<0.05)。O液的IC50为1.132mg/ml, P液的IC50为1,129 mg/ml。
④SDS-PAGE电泳结果示,O、P液含多种蛋白质,其中O液包括7条含量较高的蛋白质,其分子量分别在120kD (1kD=103),60 kD,48 kD,35 kD,33 kD,25 kD,20 kD左右。P液中存在6条含量较高的蛋白质,其分子量分别在120kD,80 kD,35 kD,33 kD,25 kD,20 kD左右。
⑤光镜下、细胞计数和MTT法示不同浓度的A、B、D、H、J、K、L、M、N液对肝癌细胞株Bel-7402的生长抑制作用不明显。
结论：
①经CL-6B、DEAE FF、Sephadex G-75得到的抗肿瘤活性成分,两者均为酸性蛋白质混合物,其分子量范围在2×104-6×104之间；
②O液和P液均能抑制Bel-7402细胞的增殖,其作用呈剂量依赖性,O、P液体外抑瘤活性较ECP总液均提高了约8.5倍；
第三章ECP总液对肝癌细胞株Bel-7402的作用及机制的研究
目的：研究ECP总液对肝癌细胞株Bel-7402中Galectin-7和p-JNK1表达的影响,并进一步探讨其作用机制。
方法：以半数抑制浓度的ECP总液(1Omg/ml)诱导肝癌细胞株Bel-7402不同时间(0h、3h、6h、12h、24h、48h),通过Western blot、Real time-PCR、免疫荧光检测细胞内Galectin-7和p-JNK1的蛋白及mRNA表达；用Galectin-7-siRNA预处理Bel-7402细胞,再予lOmg/ml ECP总液诱导48 h,观察Galectin-7的蛋白及mRNA表达和p-JNK1的蛋白表达变化。
结果：①Western blot、Real time-PCR、免疫荧光均显示,ECP总液干预呈时间依赖性上调肝癌细胞株Bel-7402中Galectin-7和p-JNK1的蛋白及mRNA,与对照组相比差异有统计学意义(P<0.01)。
②Western blot、Real time-PCR、免疫荧光均显示,Galectin-7-siRNAs可显著抑制ECP总液对Galectin-7的蛋白及mRNA表达的诱导作用,与ECP总液刺激组相比差异有统计学意义(P<0.05)。
③Western blot显示,Galectin-7-siRNAs可显著抑制ECP总液对p-JNK1蛋白表达的诱导作用,与ECP总液刺激组相比差异有统计学意义(P<0.05),与对照组相比差异有统计学意义(P<0.05)。
结论：
ECP总液呈时间依赖性上调肝癌细胞株Bel-7402中Galectin-7的蛋白及mRNA和p-JNK1的蛋白及mRNA,提示ECP总液可能通过Galectin-7-JNK途径促进肝癌细胞株Bel-7402的凋亡。
Hepatocellular carcinoma (HCC) was one of the most common malignancy tumor in worldwide. It was the third leading cause of death attributable to cancer. The incidence of 50-150 HCC cases per 100,000 population and year in parts of Africa and Asia where HCC was responsible for a large proportion of cancer deaths. In recent 20 years, despite the emergence of various therapeutic modalities such as diagnosis at an early stage, hepatic resection and radiofrequency ablation were therapy and chemotherapy. In China, HCC was the second the incidence of and mortality of cancer.
The treatment for the patient mainly depended on the stage of the tumor and the liver function. As we all known, although surgery (partial hepatectomy or total hepatectomy with orthotopic liver transplantation) could be curative for localized small liver tumors, therapeutic options for patients with advanced or metastatic HCC were limited. The patients who had no chance to undergo hepatic resection or could not bear the surgery may be cured by combination of region treatment with integration treatment. There were many methods for it, But all treatments had their own respective limitations; and the therapeutic effect for the patients with advanced stage of HCC was still poor. Further elucidation of the molecular pathogenesis of HCC and exploration of an effective drug may facilitate the development of more effective therapeutic interventions for HCC.
Centipede as a drug applied to prophylaxis and treatment of diseases had a history of more than two thousand years. The extract of whole centipede was proved to have many effects in disease treatment in recent years. But the reports about its effect in carcinomas' treatment were in odds and ends, and the method for experiment of tumor therapy only limits to MTT. Up to now, little information of its detailed mechanism of action had been known to us. In order to investigate the sensibility and mechanisms of HCC cell to extract of centipede (ECP),we took HCC Bel-7402 cell line and model of heterotopic grafting carcinoma for HCC Bel-7402 to research treatment with ECP by a series of methods.What we did aim to give its theory to clinic treatment with ECP for HCC.
ChapterⅠAssay sensibility of HCC Bel-7402 cell line to ECP in vitro
Objective:To investigate the inhibitory effect of ECP, supernatant and protein from ECP on human HCC Bel-7402 cell line.
Method: Bel-7402 cell line were cultured in vitro; ECP、the supernatant from ECP and its protein were applied to the interference of the growth of Bel-7402 with different drug concentration; MTT method and cell amounts were employed to investigate the sensibility to them. We observe cell morpheus changes through inversion light microscope. LO2 cell line was cultured in vitro. ECP were applied to the interference of the growth of LO2 with different drug concentration; MTT method and cell amounts were employed to investigate the sensibility to them.
Result:①According to light microscope and cell amounts after 48 hours, we found out that these were viable counts of Bel-7402 decrease at the ECP、the protein of ECP and 5-Fu, no evident depressant effect for cells Bel-7402 at the supernatant from ECP and for cells LO2 at the ECP.
②The result of MTT method showed that the inhibition ratio to Bel-7402 of ECP、the protein of ECP、the supernatant from ECP and 5-Fu was 0.788、0.453、0.198 and 0.944, respectively. The inhibition ratio to LO2of ECP was 0.095.
③The result of MTT method showed that the inhibition ratio of various concentration of ECP at 12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml and 0.0012mg/ml was 0.788、0.608、0.308、0.207 and 0.099, respectively, and IC50 of ECP to Bel-7402 was 9.597mg/ml. The inhibition ratio of various concentration at 2.9mg/ml、0.29mg/ml、.029mg/ml、.0029mg/ml and 0.00029mg/ml was 0.453、0.208、0.145、0.077 and 0.063, respectively, and IC50 to Bel-7402 was 1.372mg/ml.
④Drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with ECP and the protein of ECP concentration. There existed distinct discrepancies for different groups (P<0.05)
⑤The result of MTT method showed that the inhibition ratio of various concentration of ECP at 12mg/ml、1.2mg/ml、0.12mg/ml、0.012mg/ml and 0.0012mg/ml was 0.095、0.040、0.037、0.022 and 0.005, respectively.
Conclusion:
①ECP and the protein of ECP could inhibit the growth of Bel-7402 cells. The inhibitory effect was concentration dependent. The supernatant from ECP had no transparent inhibiting on Bel-7402.
②ECP had no transparent inhibition on LO2.
ChapterⅡIsolation, Purification the anti-tumor protein extracted from ECP
Objective:To investigate the sensibility of HCC Bel-7402 cell line by treatment of the protein of ECP was isolated and purified by gel filtration, ion-exchange chromatography. The molecular weights of proteins were identified by SDS-PAGE electrophoresis method.
Method:①Bel-7402 cell line were cultured in vitro. The protein of ECP was isolated and purified by gel filtration on CL-6B, DEAE-Sepharose-FF anion-exchange chromatography and gel filtration on Sephadex G-75, applied to the interference of the growth of Bel-7402 with different drug concentration; MTT method and cell amounts were employed to investigate the sensibility to them.
②We observe cell morpheus changes through inversion light microscope.
③The molecular weights of effective components were identified by SDS-PAGE.
Result:①A、B、C、D、E were separated from the protein of ECP by gel filtration on CL-6B column. According to light microscope、the cell amounts and MTT after 48 hours, we found out that the proteins compound C and E had remarkable suppressive on the proliferation of Bel-7402 in vitro. The protein molecular weights of C and E were mainly distributed between 1.6×106～2.2X 106、1×104～4×105, respectively. The result of MTT method and drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with C and E concentration. The cell proliferation was slower than that of contrast group (P＜0.05)
②F、G、H、I、J、K、L were separated from the compound C and E by DEAE-Sepharose-FF anion-exchange chromatography. According to light microscope、the cell amounts and MTT after 48 hours, we found out that the proteins compound G and I had remarkable suppressive on the proliferation of Bel-7402 in vitro. The pI of G and I less than 6.8. The result of MTT method and drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with G and I concentration. The cell proliferation was slower than that of contrast group (P＜0.05)
③M、N、O、P were separated from the compound G and I by gel filtration on Sephadex G-75 column. T According to light microscope、the cell amounts and MTT after 48 hours, we found out that the proteins compound O and P had remarkable suppressive on the proliferation of Bel-7402 in vitro. The protein molecular weights of O and P were mainly distributed between 4×104～6×104、2×104～4×104 respectively. he result of MTT method and drug concentration survival curve showed that the viable counts of Bel-7402 had direct relations with G and I concentration. The cell proliferation was slower than that of contrast group (P<0.05).IC50 of O and P to Bel-7402 was 1.132mg/ml and 1.129mg/ml, respectively.
④In SDS-PAGE,7 major bands were showed in O (molecular weights: 120Kd(1=103),60 kD,48 kD,35 kD,33 kD,25 kD,20 kD.6 major bands were showed in P (molecular weights: 120kD,80 kD,35 kD,33 kD,25 kD,20 kD).
⑤A、B、D、F、H、J、L、M、N from ECP could inhibit the growth of HCC Bel-7402 cell line at different concentration, but the growth inhibiting rate were low.
Conclusion:
①O、P were separated from the protein of ECP by gel filtration on CL-6B column、DEAE-Sepharose-FF anion-exchange chromatography、gel filtration on Sephadex G-75 column, which were compound of acidic protein. The protein molecular weights of O and P were mainly distributed between 2×104～6×104.
②O、P could inhibit the growth of the Bel-7402. The inhibitory effect was concentration dependent. And its suppressive effect on the proliferation of Bel-7402 was nearly 8.5 times more than the crude proteins of ECP.
ChapterⅢTo explore the mechanisms in human Bel-7402 cell line treated with ECP
Objective: To explore the effect of antitumor molecular mechanisms, the HCC Bel-7402 cell line were treated with ECP.
Method:Bel-7402 cells line were treated with ECP (10mg/ml) in different time (0、3、6、12、24、48h). The expression of Galectin-7 and p-JNK1 protein expression and mRNA were examined by Western Blot, Real Time-PCR and immunofluo-rescence staining. We treated Bel-7402 cells line with Galectin-7-siRNA, then Bel-7402 cells line were treated with ECP (10mg/ml) in 48h. The expression of Galectin-7 protein expression and mRNA, and p-JNK1 protein expression were examined by Western Blot, Real Time-PCR and immunofluorescence staining.
Result:
①Western Blot, Real Time-PCR and Immunofluorescence staining showed that expression of Galectin-7, p-JNK1 protein and mRNA were up regulated in a time-dependent manner in Bel-7402 stimulated with ECP. There was significantly difference among ECP groups and contrast group (P<0.01)
②Western Blot, Real Time-PCR and Immunofluorescence staining showed that expression of Galectin-7, p-JNK1 protein and mRNA were decreased in Bel-7402 stimulated with ECP in the presence of Galectin-7-siRNAs compared with Bel-7402 stimulated with ECP (P<0.05)
③Western blot showed that induction of p-JNK1 protein was decreased in Bel-7402 stimulated with ECP in the presence of Galectin-7-siRNAs compared with Bel-7402 stimulated with ECP (P<0.05). There was significantly difference amongs Galectin-7-siRNAs groups and contrast group (P<0.05)
Conclusion:
Galectin-7, p-JNK1 protein and mRNA were up regulated in a time-dependent manner in Bel-7402 stimulated with ECP. ECP maybe activate Galectin-7-JNK pathway to induce apoptosis of Bel-7402.
引文
[1]Bruix,J.Sherman,M. Management of hepatocellular carcinoma[J]. Hepatology 2005,42(5):1208-1236.
[2]Llovet, J. M. Bruix, J. Novel advancements in the management of hepatocellular carcinoma[J]. J. Hepatol.2008,48(suppl.1), s20-s37.
[3]E1-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidermiology and molecular carcinogenesis[J]. Gastroenterology,2007,132(7):2557-2576.
[4]中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会,中华医学会肝癌学会肝病分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3)：259-269.
[5]Parkin DM, Bray F,Ferlay J,et al.Global cancer statistics,2002 [J].CA Cancer J Clin,2005,55(2):74-108.
[6]刘允怡,赖俊雄,梁惠棠.全身免疫化疗治疗肝癌的效果[J].中国普外基础与临床杂志,2006,13(2)：129-131.
[7]Zhou XD,Tang ZY,Yang BH,et al.Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer,2001, 91(8):1479-1486.
[8]樊嘉,王征.原发性肝癌的外科治疗进展[J].消化外科,2006,5(6)：397-400.
[9]Yang JM,Kan T,Chen H,etal.Hepatectomy in the treatment of very big primary liver cancer:report of 86 cases[J].Hepatobiliary Pancreat DisInt,2002, 1(1):42-45.
[10]张晓华,周旭宇.漫谈肝细胞性肝癌的治疗[J].中国普通外科杂志,2006,15(7)：484-486.
[11]汤钊猷.肝癌诊治现状与展望[J].中国普外基础与临床杂志,2000,7(4)：205-207.
[12]Gaiani S,Celli N,Cecilioni L,et al.Review article:percutaneous treatment of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2003,17(Suppl2):103-110.
[13]Lopez PM, Villanueva A, Llovet JM. Systematic review:evidence-based management of hepatocellular carcinoma an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther,2006,23(11):1535-1547.
[14]Chow, P.K. Tai BC, Tan CK,et al.High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial[J]. Hepatology 2002,36(5):1221-1226.
[15]Becker, G, Allgaier, H. P, Olschewski, M., et al. Long-acting octreotide versus placebo for treatment of advanced HCC:a randomized controlled double-blind study[J]. Hepatology,2007,45(1),9-15.
[16]Llovet J M.Sale M. Castells L.et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma[J]. Hepatology,2000,31(1): 54-58.
[17]Yang T S, Lin Y C, Chen J S, et al. Phase ii study of gemcitabine in patients with advanced hepatocellular carcinoma[J]. Cancer,2000,89(4):750-756.
[18]Palmieri, G., Biondi, e., Morabito, A., et al. Thymostimulin treatment of hepatocellular carcinoma in liver cirrhosis[J]. Int. J. Oncol.1996,8(6):827-832.
[19]Kawata S.Yamasaki E. Nagase T.et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial[J]. Br. J. Cancer,2001,84(7):886-891.
[20]Hsu C. Chen CN, Chen LT. et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma[J]. Oncology,2003,65(3):242-249.
[21]Villa E. Ferretti I.Grottola A. et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors[J]. Br.J.Cancer,2001,84(7):881-885.
[22]Kern M A.Schoneweiss MM. Sahi D.et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice[J]. Carcinogenesis,2004,25(7):1193-1199.
[23]Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med 2008,359(4):378-390.
[24]陈孝平,张万广.肝细胞性肝癌实验研究的热点与展望[J].中华实验外科杂志,2006,23(3)：264-265.
[25]McCormick F.Cancer gene therapy: Fringe or cutting edge?[J].Nat Rev Cancer,2001,1(2):130-141.
[26]Jean M. Angiogenesis:A boost for tumor starvation[J].Science,2003 301(5632):452-454.
[27]Pakesh KJ.Molecular regulation of vessel maturation[J]. Nat Med,2003, 9(6):685-693.
[28]Schmitz V, Wang L, Barajas M, et al.Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice[J].Gut,2004,53(4):561-567.
[29]Lau WY, Yu SC, Lai EC, et al. Transarterial chemoembolization for hepatocellular carcinoma [J].J Am Coll Surg,2006,202 (1):155-168.
[30]潘启超,胥彬主编.肿瘤药理学与化疗学第二版[M].河南医科大学出版社,郑州,2000,315.
[31]韩双红,王玉芬,赵泰,等.君肾舒冲剂药理作用的研究[J].中草药,1999,30(4)282-284.
[32]Stankiewicz M, Hamon A, Benkhalifa R et al. Effects of a centipede venom fraction on insect nervous system, a native Xenopus oocyte receptor and on an expressed Drosophila mus2 carinic receptor[J].Toxicon, 1999,37(10):1431-1445
[33]司秋菊,王鑫国,白霞等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[34]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药,2005,28(4)：6-7.
[35]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用[J].中药材,1999,22(10)：518-519.
[36]王玉芬,韩双红,曲树明等.蜈蚣延缓衰老作用的研究[J].中国中药杂志,1994,19(11)：685-687.
[37]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[38]任丽虹,郝立君,段国新等.五倍子、蜈蚣对瘢痕疙瘩成纤维细胞增殖和胶原合成的影响[J].实用美容整形外科杂志,2003,14(6)：324-327.
[39]李厚伟,张妍,许超千等.中药HB对喉癌Hep22细胞的抑制作用及其机制研 究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[40]刘国清,田秉漳,皮执民等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[41]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[42]刘细平,陈宏伟,钟德玝.蜈蚣提取液对肝癌Bel-7404细胞体外抗癌作用的研究[J].现代中西医结合杂志,2009,18(32)：3935-3938.
[43]刘翔峰.蜈蚣醇提液的毒理学研究及对肝癌细胞株Bel-7402生物学影响[D].中南大学,2008.
[44]Steven SS, Chang CK, Liu HS.Step change of mobil phase flow rates to enhance protein folding in size exclusion chromatography [J]. Biochem Eng J,2006, 29(1-2):2-11.
[45]Tsutmu A, Kouhei T, Kazuo N, et al. The effects of arginine on protein binding and elution in hydrophobic interaction and ion-exchange chromatography [J]. Protein Expr Purif,2007,54(1):110-116.
[46]Shuichi Y, T oshohiko K, Taksshi I. Application of a chromatography model with linear gradient elution experimental data to the rapid scale-up in ion-exchange process chromatography of protein [J]. J Chromatogr A,2007,1162(1):34-40.
[47]Madsen P, Rasmussen HH, Flint T, et al. Cloning, expression, and chromosome mapping of human galectin-7 [J].JBiol Chem 1995,270(11):5823-5829.
[48]Kuwabara I, Kuwabara Y, Yang RY, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release[J]. JBiol Chem,2002,277(5):3487-3497.
[49]Matsui Y, Ueda S, Watanabe J, et al. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species[J]. Cancer Res,2007,67(3):1212-1220.
[50]张丽.蜈蚣抗肿瘤蛋白的分离纯化与药理机制初探[D].北京中医药大学,2007.
[51]孙媛媛,葛瑞良,于凤海.原发性肝癌的非手术治疗进展[J]肿瘤,2008,28(10)：900-903.
[52]吴孟超,程树群.肝癌微创外科治疗的现状和展望[J].中国微创外科杂志,2005,5(2)：85-87.
[53]Lau WY. Primary hepatocellular carcinoma [A].Sermin Surg Oncol.2000,9(2): 135-144.
[54]Lau WY. Management of hepatocellular carcinoma [J].J R Coll Surg Edinb, 2002,47 (1):389-399.
[55]Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres [J]. Int J Radiat Oncol Biol Phys,1998,40(3):583-592.
[56]方红,邓芬,王克勤.多棘蜈蚣化学成分的研究[J].中国药学杂志,1997,32(4)202-204.
[57]徐叔云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,2005：1192-1194.
[58]Yajun G,Mengchao W, Han C, et al. Effective tumor vaccines generated by fusion of hepatoma cells[J].Science,1994,263(5146):518-524.
[59]Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines[J].Curr Opin in Immu,2000,12(5):583-591.
[60]周程,胡思安,龚绍等,胆囊癌对化疗药物敏感性的研究[J].中华现代外科学杂志,2005,20(2)：1830-1832.
[61]谢诚,钱美英,缪丽燕.MTT法测定肝癌细胞药物敏感性与临床用药[J].药学与临床研究,2007,15(5)：393-395.
[62]赵斌,葛金芳,朱娟娟等.小议在MTT法测细胞增殖抑制率中IC50的计算方法[J].安徽医药,2007,11(9)：834-836.
[63]徐建明,汤仲明,宋三泰等.人乳腺癌原代培养体外药敏试验的评价[J].中华肿瘤杂志,1995,17(2)：100-102.
[64]吴孟超.中医药在HCC防治中的作用、地位和存在的问题[J].中西医结合学报,2003,1(3)：163-164.
[65]刘峰.蜈蚣的临床应用及毒性研究[J].广西中医药,1999,22(4)：52-53.
[66]焦波,娄红祥,王东兴等蜈蚣提取物对小鼠精原细胞的作用[J],山东医科大学 学报,1999,37(4)：3581.
[67]李风云,陈浩然,张蓄兰等.中药制剂抗肿瘤作用的实验研究[J],中医药学报,1999,27(5)：571.
[68]Joffe JK, Perren TJ, Bradley C, et al. A phase Ⅱ study of recom-binant interferon-beta in combination with 5-fluorouracil in the treatment of patients with advanced colorectal carcinoma[J]. Br J Cancer,1997,75 (3):423～426.
[69]陈孝治主编,药物处方手册,湖南科学技术出版社,2005,871.
[70]李慧,吴恩应,张彦鹏等人血清IgG分离纯化方法探讨[J].广西大学学报(自然科学版),2008,33(sup)：109-112.
[71]刘细平.蜈蚣提取液治疗肝细胞肝癌的实验研究[D].中南大学,2007.
[72]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌抑癌作用及机制的研究[J].中国普通外科杂志.2010,19(2)：164-168.
[73]刘细平,钟德玝,王劲等.蜈蚣提取液对裸鼠移植肝癌治疗作用研究[J].现代中西医结合杂志,2010,19(15)：1842-1844.
[74]Morizane Y, Honda R, Fukami K, et al. X-linked inhibitor of apoptpsis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLLO[J]. J Biochem(Tokyo),2005,137(2):125-132.
[75]魏淑燕,乔福元XIAP Bax mRNA在妊娠期高血压疾病胎盘中的表达及其意义[J].中国优生与遗传杂志,2005,13(3)：36-38.
[76]胡晓倩,陈来同,陈雅蕙等。凝胶过滤分离蛋白质实验条件的研究[J].中国生化药物杂志,2007,28(6)：409-411.
[77]萧能,余瑞元,陈雅蕙等.生物化学实验原理和方法(第二版)[M].北京：北京大学出版社,2005：250-261.
[78]高艳利,杨思文,樊凯奇等,SDS-PAGE电泳技术分析蛋白质的研究[J].辽宁化工,2007,36(7)：460-463.
[79]Gomez N, Cohen P. Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases[J]. Nature,1991,353(6340):170-173.
[80]Moisan S, Demers M, Mercier J, et al. Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype[J]. Leukemia,2003,17(4):751-759.
[81]Zhu H, Pei HP, Zeng S, et al. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma[J]. J Proteome Res,2009,8(8):3969-3976.
[82]Demers M, Biron-Pain K, Hebert J, et al. Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model[J]. Cancer Res, 2007,67(6):2824-2829.
[83]Langbein S, Brade J, Badawi JK, et al. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance[J]. Histopathology,2007,51(5):681-690.
[84]段艳,王冰,崔韶辉等,阳离子脂质体转染Hela细胞的实验[J].中国组织工程研究与临床康复,2009,13(11)：2119-2122.
[85]马百超,张树彪,王冰等.细胞种类对阳离子脂质体介导基因转染的影响[J].安徽农业科学,2008,36(14)：5779-5781.
[86]Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins[J]. JBiol Chem,1994,269(33):20807-20810.
[87]Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages[J]. J Immunol,2000,165(4):2156-2164.
[88]Chen J, He QY, Yuen AP, et al. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis[J]. Proteomics,2004, 4(8):2465-2475.
[89]Magnaldo T, Fowlis D, Darmon M: Galectin-7, a marker of all types of stratified epithelia[J]. Differentiation,1998,63(3):159-168.
[90]Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis[J]. Nature, 1997,389(6648):300-305.
[91]Sigal A, Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome[J]. Cancer Res,2000,60 (24):6788-6793.
[92]Inagaki Y, Higashi K, Kushida M, etal. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7[J]. Gastroenterology.2008,134(4):1180-1190.
[93]Demers M, Magnaldo T, St-Pierre Y. A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression[J]. Cancer Res,2005, 65 (12):5205-5210.
[94]Kennedy NJ, Davis RJ, Role of JNK in tumor development[J].Cell Cycle 2003,2(3):199-201.
[95]Suzuki T, Tsukamoto I. Manganese-induced apoptosis in hepatocytes after partial hepatectomy[J]. Eur J Pharmacol,2005,525(1-3):48-53.
[96]Kuwabara I, Kuwabara Y, Yang RY, et al. Galectin-7 (PIG1) exhibits proapoptotic function through JNK activation and mitochondrial cytochrome c release[J].J.Biol.Chem.2002,277(5):3487-3497.
[97]Matsui Y, Ueda S, Watanabe J, et al. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species[J]. Cancer Res.2007,67(3):1212-1220.
[1]Bruix,J.Sherman,M. Management of hepatocellular carcinoma[J]. Hepatology 2005,42(5):1208-1236.
[2]Llovet, J. M. Bruix, J. Novel advancements in the management of hepatocellular carcinoma[J]. J. Hepatol.2008,48(suppl.1), s20-s37.
[3]Parkin DM, Bray F,Ferlay J,et al.Global cancer statistics,2002 [J].CA Cancer J Clin,2005,55(2):74-108.
[4]中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会,中华医学会肝癌学会肝病分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3)：259-269.
[5]Lopez PM, Villanueva A, Llovet JM. Systematic review:evidence-based management of hepatocellular carcinoma an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther,2006,23(11):1535-1547.
[6]Chow, P.K. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma:a multicenter randomized controlled trial[J]. Hepatology 2002,36(5): 1221-1226.
[7]Yuen M F.Poon RT.Lai ST. et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma[J]. Hepatology,2002,36(3):687-691.
[8]Becker, G., Allgaier, H. P, Olschewski, M., et al. Long-acting octreotide versus placebo for treatment of advanced HCC:a randomized controlled double-blind study[J]. Hepatology,2007,45(1):9-15.
[9]Llovet J M.Sale M. Castells L.et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma[J]. Hepatology,2000,31(1): 54-58.
[10]Yang T S, Lin Y C, Chen J S, et al. Phase ii study of gemcitabine in patients with advanced hepatocellular carcinoma[J]. Cancer,2000,89(4):750-756.
[11]Kubicka, s., rudolph, K. L., Tietze, M. K., et al Phase ii study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas[J]. Hepatogastroenterology.2001,48(39):783-789.
[12]Palmieri, G., Biondi, e., Morabito, A., et al. Thymostimulin treatment of hepatocellular carcinoma in liver cirrhosis[J]. Int. J. Oncol.1996,8(6):827-832.
[13]Stefanini G F. Foschi F G, Castelli E.et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients:a preliminary experience[J]. Hepatogastroenterology,1998,45(19):209-215.
[14]Kawata S.Yamasaki E. Nagase T.et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial[J]. Br. J. Cancer,2001,84(7):886-891.
[15]Hsu C. Chen CN, Chen LT. et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma[J]. Oncology,2003,65(3):242-249.
[16]Villa E. Ferretti I.Grottola A. et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors[J].Br.J.Cancer,2001,84(7):881-885.
[17]Kern M A.Schoneweiss MM. Sahi D.et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice[J]. Carcinogenesis,2004,25(7):1193-1199.
[18]Wada A.Fukui K. Sawai Y.et al. Pamidronate induced antiproliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma[J]. J. Hepatol,2006,44(1): 142-150.
[19]Zhu, A. X. systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? [J] Oncologist 2006,11(7):790-800.
[20]Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival[J]. Hepatology 2003,37(2):429-442.
[21]周信达.肝癌复发转移的研究进展[J].世界华人消化杂志.1999,7(3)：260-261.
[22]聂永梅,杨洁,罗超权,杨英洁,伍新尧.肝癌细胞膜受体含pRSVB7特异性配基的构建[J].世界华人消化杂志.2000,8(1)：63-66.
[23]Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus[J]. Ann Intern Med,2003,138(4):299-306.
[24]Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356(9232):802-807.
[25]Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors[J]. J Clin Oncol,2004,22(8):1389-1397.
[26]Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas [J]. J Clin Oncol,2005,23(5): 999-1010.
[27]Schueller G, Stift A, Friedl J, et al. Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells[J].Int J Oncol,2003,22(6):1397-1402.
[28]Palmer DH, Midgley RS, Mirza N, et al A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology,2009,49(1):124-132.
[29]Kuang M, Peng BG, Lu MD, et al.Phase Ⅱ randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma [J]. Clin Cancer Res,2004,10(5):1574-1579.
[30]Geissler M, Mohr L, Dohler G, et al. Immunotherapy directed against alpha— fetoprotein results in autoimmune liver disease during liver regeneration in mice[J]. Gastroenterology,2001,121(4):931-939.
[31]Butterfield LH, Ribas A,Meng WS, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer [J]. Clin Cancer Res,2003,9(16):5902-5908.
[32]Butterfield LH, Ribas A, Dissette VB, et al. A phase Ⅰ/Ⅱ trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides [J]. Clin Cancer Res,2006,12(9): 2817-2825.
[33]汤勇,周训平,王晓芹.原发性肝癌的基因治疗进展[J].局解手术学杂志,2009,18(3)：202-203.
[34]Jicai Z, Zongtao Y, Jun L, et al. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma[J].Mol Carcinog,2006,45(7):530-536.
[35]Zhang YJ, Rossner P Jr, Chen Y, et al.Aflatoxin B1 and polyc-yclic aromatic hydrocarbon adducts,p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients[J].Int J Cancer,2006,119(5): 985-991.
[36]穆红,王玉亮,刘蓉.野生型p53基因在人肝癌细胞的表达及诱导其凋亡[J].细胞与分子免疫学杂志,2006,22(6)：758-759.
[37]Huang JZ, Shen WI, Ii B, et al.Molecular and immunohisto-chemical study of theinactivation of the p16 gene in prima ryhepatocellular carcinoma[J]. Chin Med J,2000,113(9):889-893.
[38]Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy [J]. Gene Ther,2002,9(3):168-175.
[39]Won YS, Lee SW. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA [J]. J B iotechnol,2007,129(4):614-619.
[40]Harada Y, Iwai M, Tanaka S, et al. Highly efficient suicide gene expression in hepatocellular carcinoma cells by epstein-barr virus-based plasmid vectors combined with polyamidoamine dendrimer [J].Cancer Gene Ther,2000, 7(1):27-36.
[41]Wang XW, Yuan JH, Zhang RG, et al. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonuc-leotides in vitro and in mice[J]. World J Gastroenterol,2001,7(3):345-351.
[42]Sun Y, Lin R, Dai J, et al. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nudemice[J]. Oligonucleotides,2006,16(4): 365-374.
[43]Gu S, Liu CJ, Qiao T, et al. Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells[J].World J Gastroenterol.2004,10(4):535-539.
[44]李华,王欣璐,杨扬等RNAi靶向人端粒酶逆转录酶对人肝癌细胞的生长抑制作用[J].南方医科大学学报,2008,28(8)：1323-1326.
[45]Krause, D. s.& van etten, r. A. Tyrosine kinases as targets for cancer therapy [J]. N. Engl. J. Med.2005,353(2):172-187.
[46]Llovet JM, Bruix J.Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology.2008,48(4):1312-1327.
[47]Roberts LR. Sorafenib in liver cancer—just the beginning[J]. N Engl J Med 2008;359(4):420-422.
[48]Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J]. Cancer Chemother Pharmacol.2007,59 (5):561-574.
[49]Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med.2008,359(4):378-390.
[50]Goodman VL,Rock EP,Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma[J]. Clin Cancer Res,2007,13(5):1367-1337.
[51]Faivre SJ,Raymond E, Douillard J, et al. A ssessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC)[J]. Pro Am Soc Clin Oncol,2007, abstr 3546.
[52]Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts)with advanced hepatocellular carcinoma(HCC): Preliminary results of a phase Ⅱ study with circulating endothelial cell (CEC) monitoring [J]. Journal of Clinical Oncology,2007,25(18Suppl):4570.
[53]ZHU A X, BLASZKOW SKY L S, RYAN D P, et al. Phase Ⅱ study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma [J]. J Clin Oncol,2006,24(12):1898-1903.
[54]Hsu C,Cheng JC, Cheng AL, et al.Recent advances in non-surgical treatment for advanced hepatocellular carcinoma[J]. J FormosMed Assoc, 2004,103(7):483-495.
[55]Fazio N, Petralia G, Mancuso P, et al. Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study[J].Journal of Clinical Oncology,2007,25(18Suppl):15076.
[56]Chuah B, Lira R, Boyer M, et al. Multi-centre phase Ⅱ trial of thalidomide in the treatment of unresectable hepatocellular careinoma [J]. Acta Oncol,2007,46(2): 234-238.
[57]Schwartz JD, Sung M, Schwartz M,et al.Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha-a upon progression[J]. Oncologist,2005,10(9):718-727.
[58]Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor singnaling in human hepatocellular carcinoma [J]. Oncogene,2006,25(27): 3787-3800.
[59]O' Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group' s Study E1203[J]. Journal of Clinical Oncology,2006, 24(18Suppl):4143.
[60]Thomas MB, Chadha R, Glover K. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma [J]. Cancer,2007,110(5):1059-1067.
[61]Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma [J]. Cancer,2007,110(3):581-589.
[62]吴孟超.中医药在HCC防治中的作用、地位和存在的问题[J].中西医结合学报,2003,1(3)：163-164.
[63]陈洪,秦叔逵,陈惠英等.三氧化二砷抗肝癌作用的实验研究[J].中华肝脏病杂志,2000,8(1)：27-29.
[64]刘健,高建辉,刘晓秋.斑蝥素及其衍生物的研究进展[J].中药材,2003,26(6)：453-455.
[65]丰俊东,徐晓玉.川芎嗪含药血清对人肝癌细胞Bel-7402增殖的抑制作用[J].中草药,2005,36(4)：551-553.
[66]Deng X,Yin F,Lu X, et al.The apoptotic effect of brucine from the seed of Strychnos nux-vomica on human hepatoma cells is mediated via Bcl-2 and Ca2+ involved mitochondrial pathway[J].Toxicol Sci,2006,91(1):59-69.
[67]Deng X K,Yin W, Li W D,et al. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on Bel-7402 cells and its possible mechanism [J].J Ethnopharmacol,2006,106(2):179-186.
[68]Wang Q F,Chiang C W,Wu C C,et al.Gypenosides induce apoptosis in human hepatoma Huh27 cells through a calcium/reactive oxygen species-dependent m itochondrial pathway[J].Planta Med,2007,73(6):535-544.
[69]张晨,李柏,吕书勤等.蜂毒素对人肝癌细胞线粒体膜蛋白7A6和凋亡相关基因产物Fsa及其配体FasL表达的影响[J].中西医结合学报,2007,5(5)：559-562.
[70]朱青,张王刚,王立锋等.白藜芦醇诱导肿瘤细胞凋亡和细胞周期阻滞的作用及机制[J].第四军医大学学报,2005,26(21)：1935-1937.
[71]Liu T Z,Cheng J T,Yiin S J,et al.Isoobtusilactone a induces both caspase-dependent and-independent apoptosis in Bel-7402 cells [J]. Food Chem Toxicol,2008,46(1):321-327.
[72]Sa F, Gao J L,Fung K P,et al. Anti-proliferative and pro-apoptotic effect of Smilax glabra Roxb extract on hepatoma cell lines [J]. Chem Biol Interact,2008, 171(1):1-14.
[73]Hsu Y L, Kuo P L, Tzeng T F, et al. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo[J].J Gastroenterol Hepatol.2008,23(7 Pt2):290-299.
[74]Chan J Y, Tang P M, Hon P M, et al.Pheophorbidea, a major antitumor component purified from Scutellaria barbata,induces apoptosis in human hepatocellular carcinoma cells [J].Planta Med,2006,72(1):28-33.
[75]刘细平,陈宏伟,钟德玝.蜈蚣提取液对肝癌Bel-7404细胞体外抗癌作用的研究[J].现代中西医结合杂志,2009,18(32)：3935-3938.
[76]WuX Z, Chen D,Xie G R. Effects of Gekko sulfated polysaccharides on the proliferation and differentiation of hepatic cancer cell line[J]. Cell Biol Int,2006, 30(8):659-664.
[77]刘平,周建锋,胡义扬等.益气养阴诱导SMMC-7721肝癌细胞分化作用与意义[J].中国中医基础医学杂志,2000,6(8)：29-34.
[78]孟志强,于尔辛,宋明志等.健脾理气中药对肝癌端粒酶活性的影响[J].中国中医基础医学杂志,2000,6(1)：23-26.
[79]陈规划,张俊峰,陆敏强等.冬凌草甲素诱导肝癌细胞凋亡中Bcl-2及端粒酶变化的研究[J].中国中药杂志,2006,31(21)：1811-1814.
[80]张振宇,张赤志,许汉林等.皂荚提取物对人肝癌细胞相关癌基因表达的调控作用及端粒酶的影响[J].中西医结合肝病杂志,2008,18(2)：93-95.
[81]楼芳,秦叔逵,陈惠英.三氧化二砷对人类肝癌细胞株端粒酶活性的影响[J].临床肿瘤学杂志,2006,11(4)：250-253.
[82]朱灵,韦晓谋,杨春旭.蝎毒对人肝癌细胞Bel-7404凋亡及端粒酶逆转录酶基因的作用[J].广西医学,2008,30(2)：158-160.
[83]王新杰,郭勇义.益气健脾冲剂对转移性肝癌造模大鼠的影响[J].中医研究,2006,19(8)：11-13.
[84]Liu S,Yu M, He Y, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Racl-dependent pathway[J]. Hepatology, 2008,47(6):1964-1973.
[85]华海清,孙小昆,秦叔逵等.人参皂苷Rg3抗人肝癌细胞株侵袭和转移的实验研究[J].中国癌症杂志,2005,15(4)：326-330.
[86]韩盈,杨长春.活血化瘀药物对肝癌细胞Bel-7402的抑制作用及机制[J].解放军药学学报,2006,22(6)：401-404.
[87]丰俊东,徐晓玉.川芎嗪含药血清对人肝癌细胞Bel-7402增殖的抑制作用[J].中草药,2005,36(4)：551-553.
[88]郑国灿,李智英.丹参酮Ⅰ抗肿瘤作用及作用机制的实验研究[J].实用肿瘤杂志,2005,20(1)：33-35.
[89]丁罡,宋明志,于尔辛等.丹参、赤芍对大鼠Walker256癌肝转移影响机制的研究[J].中国癌症杂志,2001,11(4)：364-366.
[90]刘明章,黄贻穗,肖伟琪等.丹参酮ⅡA磺酸钠对Lewis癌无促进生长与转移 作用[J].中国药理学报,1991,12(6)：534-536.
[91]Zhu X F,Xie B F,Zhou J M, et al. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-Ⅲ (2',4'-dihydroxy-6-methoxy-3',5'-dimethylchal-cone), a component from Chinese herbal medicine [J].Mol Pharmacol,2005,67 (5):1444-1450.
[92]施京红,刘德传,吴仕九等.清香散对湿热型肝癌模型大鼠细胞凋亡、肿瘤血管生成的影响[J].陕西中医,2004,25(1)：84-86.
[93]华海清,秦叔逵,王锦鸿等.三氧化二砷抗肿瘤血管形成研究[J].世界华人消化杂志,2004,12(1)：27-31.
[94]何芳,曾文铤,朱科伦.人参皂苷Rg3抑制肝癌移植新生血管形成的研究[J].河南科技大学学报：医学版,2005,23(4)：245-247.
[95]王谦,张玲,毛海婷等.中药淫羊藿苷抑制肝癌Bel-7402.细胞增殖和免疫逃逸作用研究[J].中国免疫学杂志,2007,23：908-911.
[96]胡玲,王洪琦,崔娜娟等.白花蛇舌草对小鼠活体腹水H22肝癌细胞及T细胞的影响[J].广州中医药大学学报,2007,24(4)：313-316.
[97]吴英德,刘宗河,康平等.复方金蒲片治疗肝癌对铜、锌、硒元素水平及免疫功能影响的观察[J].广西医学,2006,28(11)：1692-1693.
[98]Thomas H, Coley H M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycop rotein [J]. Cancer Control,2003, 10(2):159-165.
[99]李起,刘作金,张俊等.中药复方肝癌-1号逆转肝癌多药耐药的实验研究[J].消化外科,2006,5(1)：70-73.
[100]梅英,石毓君,左国庆.川芎嗪逆转细胞肝癌细胞株Bel-7402/ADM多药耐药性的体外研究[J].中国中药杂志,2004,10(29)：970-973.
[101]朱建强,韩晓红,薛延军.中药柴胡提取物对人肝癌Bel-7402细胞内游离钙离子浓度和细胞内VCR蓄积的影响[J].北华大学学报,2005,6(1)：62-64.
[2]Llovet, J. M. Bruix, J. Novel advancements in the management of hepatocellular carcinoma[J]. J. Hepatol.2008,48(suppl.1), s20-s37.
[3]E1-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidermiology and molecular carcinogenesis[J]. Gastroenterology,2007,132(7):2557-2576.
[4]中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会,中华医学会肝癌学会肝病分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3)：259-269.
[5]Parkin DM, Bray F,Ferlay J,et al.Global cancer statistics,2002 [J].CA Cancer J Clin,2005,55(2):74-108.
[6]刘允怡,赖俊雄,梁惠棠.全身免疫化疗治疗肝癌的效果[J].中国普外基础与临床杂志,2006,13(2)：129-131.
[7]Zhou XD,Tang ZY,Yang BH,et al.Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma[J]. Cancer,2001, 91(8):1479-1486.
[8]樊嘉,王征.原发性肝癌的外科治疗进展[J].消化外科,2006,5(6)：397-400.
[9]Yang JM,Kan T,Chen H,etal.Hepatectomy in the treatment of very big primary liver cancer:report of 86 cases[J].Hepatobiliary Pancreat DisInt,2002, 1(1):42-45.
[10]张晓华,周旭宇.漫谈肝细胞性肝癌的治疗[J].中国普通外科杂志,2006,15(7)：484-486.
[11]汤钊猷.肝癌诊治现状与展望[J].中国普外基础与临床杂志,2000,7(4)：205-207.
[12]Gaiani S,Celli N,Cecilioni L,et al.Review article:percutaneous treatment of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2003,17(Suppl2):103-110.
[13]Lopez PM, Villanueva A, Llovet JM. Systematic review:evidence-based management of hepatocellular carcinoma an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther,2006,23(11):1535-1547.
[14]Chow, P.K. Tai BC, Tan CK,et al.High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial[J]. Hepatology 2002,36(5):1221-1226.
[15]Becker, G, Allgaier, H. P, Olschewski, M., et al. Long-acting octreotide versus placebo for treatment of advanced HCC:a randomized controlled double-blind study[J]. Hepatology,2007,45(1),9-15.
[16]Llovet J M.Sale M. Castells L.et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma[J]. Hepatology,2000,31(1): 54-58.
[17]Yang T S, Lin Y C, Chen J S, et al. Phase ii study of gemcitabine in patients with advanced hepatocellular carcinoma[J]. Cancer,2000,89(4):750-756.
[18]Palmieri, G., Biondi, e., Morabito, A., et al. Thymostimulin treatment of hepatocellular carcinoma in liver cirrhosis[J]. Int. J. Oncol.1996,8(6):827-832.
[19]Kawata S.Yamasaki E. Nagase T.et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial[J]. Br. J. Cancer,2001,84(7):886-891.
[20]Hsu C. Chen CN, Chen LT. et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma[J]. Oncology,2003,65(3):242-249.
[21]Villa E. Ferretti I.Grottola A. et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors[J]. Br.J.Cancer,2001,84(7):881-885.
[22]Kern M A.Schoneweiss MM. Sahi D.et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice[J]. Carcinogenesis,2004,25(7):1193-1199.
[23]Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med 2008,359(4):378-390.
[24]陈孝平,张万广.肝细胞性肝癌实验研究的热点与展望[J].中华实验外科杂志,2006,23(3)：264-265.
[25]McCormick F.Cancer gene therapy: Fringe or cutting edge?[J].Nat Rev Cancer,2001,1(2):130-141.
[26]Jean M. Angiogenesis:A boost for tumor starvation[J].Science,2003 301(5632):452-454.
[27]Pakesh KJ.Molecular regulation of vessel maturation[J]. Nat Med,2003, 9(6):685-693.
[28]Schmitz V, Wang L, Barajas M, et al.Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice[J].Gut,2004,53(4):561-567.
[29]Lau WY, Yu SC, Lai EC, et al. Transarterial chemoembolization for hepatocellular carcinoma [J].J Am Coll Surg,2006,202 (1):155-168.
[30]潘启超,胥彬主编.肿瘤药理学与化疗学第二版[M].河南医科大学出版社,郑州,2000,315.
[31]韩双红,王玉芬,赵泰,等.君肾舒冲剂药理作用的研究[J].中草药,1999,30(4)282-284.
[32]Stankiewicz M, Hamon A, Benkhalifa R et al. Effects of a centipede venom fraction on insect nervous system, a native Xenopus oocyte receptor and on an expressed Drosophila mus2 carinic receptor[J].Toxicon, 1999,37(10):1431-1445
[33]司秋菊,王鑫国,白霞等.蜈蚣对动脉粥样硬化家兔血液流变学的影响[J].中国老年学杂志,2004,24(9)：831-833.
[34]梁洁,黄华营.药用蜈蚣的化学成分及药理活性研究近况[J].广西中医药,2005,28(4)：6-7.
[35]张维文,罗健东,张贵平.蜈蚣水提物对动物消化功能的增强作用[J].中药材,1999,22(10)：518-519.
[36]王玉芬,韩双红,曲树明等.蜈蚣延缓衰老作用的研究[J].中国中药杂志,1994,19(11)：685-687.
[37]贺巍,叶海英.中药蜈蚣的研究进展[J].中药材,2002,25(2)：152-155.
[38]任丽虹,郝立君,段国新等.五倍子、蜈蚣对瘢痕疙瘩成纤维细胞增殖和胶原合成的影响[J].实用美容整形外科杂志,2003,14(6)：324-327.
[39]李厚伟,张妍,许超千等.中药HB对喉癌Hep22细胞的抑制作用及其机制研 究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[40]刘国清,田秉漳,皮执民等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[41]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[42]刘细平,陈宏伟,钟德玝.蜈蚣提取液对肝癌Bel-7404细胞体外抗癌作用的研究[J].现代中西医结合杂志,2009,18(32)：3935-3938.
[43]刘翔峰.蜈蚣醇提液的毒理学研究及对肝癌细胞株Bel-7402生物学影响[D].中南大学,2008.
[44]Steven SS, Chang CK, Liu HS.Step change of mobil phase flow rates to enhance protein folding in size exclusion chromatography [J]. Biochem Eng J,2006, 29(1-2):2-11.
[45]Tsutmu A, Kouhei T, Kazuo N, et al. The effects of arginine on protein binding and elution in hydrophobic interaction and ion-exchange chromatography [J]. Protein Expr Purif,2007,54(1):110-116.
[46]Shuichi Y, T oshohiko K, Taksshi I. Application of a chromatography model with linear gradient elution experimental data to the rapid scale-up in ion-exchange process chromatography of protein [J]. J Chromatogr A,2007,1162(1):34-40.
[47]Madsen P, Rasmussen HH, Flint T, et al. Cloning, expression, and chromosome mapping of human galectin-7 [J].JBiol Chem 1995,270(11):5823-5829.
[48]Kuwabara I, Kuwabara Y, Yang RY, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome c release[J]. JBiol Chem,2002,277(5):3487-3497.
[49]Matsui Y, Ueda S, Watanabe J, et al. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species[J]. Cancer Res,2007,67(3):1212-1220.
[50]张丽.蜈蚣抗肿瘤蛋白的分离纯化与药理机制初探[D].北京中医药大学,2007.
[51]孙媛媛,葛瑞良,于凤海.原发性肝癌的非手术治疗进展[J]肿瘤,2008,28(10)：900-903.
[52]吴孟超,程树群.肝癌微创外科治疗的现状和展望[J].中国微创外科杂志,2005,5(2)：85-87.
[53]Lau WY. Primary hepatocellular carcinoma [A].Sermin Surg Oncol.2000,9(2): 135-144.
[54]Lau WY. Management of hepatocellular carcinoma [J].J R Coll Surg Edinb, 2002,47 (1):389-399.
[55]Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres [J]. Int J Radiat Oncol Biol Phys,1998,40(3):583-592.
[56]方红,邓芬,王克勤.多棘蜈蚣化学成分的研究[J].中国药学杂志,1997,32(4)202-204.
[57]徐叔云,卞如濂,陈修.药理实验方法学[M].北京：人民卫生出版社,2005：1192-1194.
[58]Yajun G,Mengchao W, Han C, et al. Effective tumor vaccines generated by fusion of hepatoma cells[J].Science,1994,263(5146):518-524.
[59]Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines[J].Curr Opin in Immu,2000,12(5):583-591.
[60]周程,胡思安,龚绍等,胆囊癌对化疗药物敏感性的研究[J].中华现代外科学杂志,2005,20(2)：1830-1832.
[61]谢诚,钱美英,缪丽燕.MTT法测定肝癌细胞药物敏感性与临床用药[J].药学与临床研究,2007,15(5)：393-395.
[62]赵斌,葛金芳,朱娟娟等.小议在MTT法测细胞增殖抑制率中IC50的计算方法[J].安徽医药,2007,11(9)：834-836.
[63]徐建明,汤仲明,宋三泰等.人乳腺癌原代培养体外药敏试验的评价[J].中华肿瘤杂志,1995,17(2)：100-102.
[64]吴孟超.中医药在HCC防治中的作用、地位和存在的问题[J].中西医结合学报,2003,1(3)：163-164.
[65]刘峰.蜈蚣的临床应用及毒性研究[J].广西中医药,1999,22(4)：52-53.
[66]焦波,娄红祥,王东兴等蜈蚣提取物对小鼠精原细胞的作用[J],山东医科大学 学报,1999,37(4)：3581.
[67]李风云,陈浩然,张蓄兰等.中药制剂抗肿瘤作用的实验研究[J],中医药学报,1999,27(5)：571.
[68]Joffe JK, Perren TJ, Bradley C, et al. A phase Ⅱ study of recom-binant interferon-beta in combination with 5-fluorouracil in the treatment of patients with advanced colorectal carcinoma[J]. Br J Cancer,1997,75 (3):423～426.
[69]陈孝治主编,药物处方手册,湖南科学技术出版社,2005,871.
[70]李慧,吴恩应,张彦鹏等人血清IgG分离纯化方法探讨[J].广西大学学报(自然科学版),2008,33(sup)：109-112.
[71]刘细平.蜈蚣提取液治疗肝细胞肝癌的实验研究[D].中南大学,2007.
[72]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌抑癌作用及机制的研究[J].中国普通外科杂志.2010,19(2)：164-168.
[73]刘细平,钟德玝,王劲等.蜈蚣提取液对裸鼠移植肝癌治疗作用研究[J].现代中西医结合杂志,2010,19(15)：1842-1844.
[74]Morizane Y, Honda R, Fukami K, et al. X-linked inhibitor of apoptpsis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLLO[J]. J Biochem(Tokyo),2005,137(2):125-132.
[75]魏淑燕,乔福元XIAP Bax mRNA在妊娠期高血压疾病胎盘中的表达及其意义[J].中国优生与遗传杂志,2005,13(3)：36-38.
[76]胡晓倩,陈来同,陈雅蕙等。凝胶过滤分离蛋白质实验条件的研究[J].中国生化药物杂志,2007,28(6)：409-411.
[77]萧能,余瑞元,陈雅蕙等.生物化学实验原理和方法(第二版)[M].北京：北京大学出版社,2005：250-261.
[78]高艳利,杨思文,樊凯奇等,SDS-PAGE电泳技术分析蛋白质的研究[J].辽宁化工,2007,36(7)：460-463.
[79]Gomez N, Cohen P. Dissection of the protein kinase cascade by which nerve growth factor activates MAP kinases[J]. Nature,1991,353(6340):170-173.
[80]Moisan S, Demers M, Mercier J, et al. Upregulation of galectin-7 in murine lymphoma cells is associated with progression toward an aggressive phenotype[J]. Leukemia,2003,17(4):751-759.
[81]Zhu H, Pei HP, Zeng S, et al. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma[J]. J Proteome Res,2009,8(8):3969-3976.
[82]Demers M, Biron-Pain K, Hebert J, et al. Galectin-7 in lymphoma: elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model[J]. Cancer Res, 2007,67(6):2824-2829.
[83]Langbein S, Brade J, Badawi JK, et al. Gene-expression signature of adhesion/growth-regulatory tissue lectins (galectins) in transitional cell cancer and its prognostic relevance[J]. Histopathology,2007,51(5):681-690.
[84]段艳,王冰,崔韶辉等,阳离子脂质体转染Hela细胞的实验[J].中国组织工程研究与临床康复,2009,13(11)：2119-2122.
[85]马百超,张树彪,王冰等.细胞种类对阳离子脂质体介导基因转染的影响[J].安徽农业科学,2008,36(14)：5779-5781.
[86]Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins[J]. JBiol Chem,1994,269(33):20807-20810.
[87]Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages[J]. J Immunol,2000,165(4):2156-2164.
[88]Chen J, He QY, Yuen AP, et al. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis[J]. Proteomics,2004, 4(8):2465-2475.
[89]Magnaldo T, Fowlis D, Darmon M: Galectin-7, a marker of all types of stratified epithelia[J]. Differentiation,1998,63(3):159-168.
[90]Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis[J]. Nature, 1997,389(6648):300-305.
[91]Sigal A, Rotter V: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome[J]. Cancer Res,2000,60 (24):6788-6793.
[92]Inagaki Y, Higashi K, Kushida M, etal. Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7[J]. Gastroenterology.2008,134(4):1180-1190.
[93]Demers M, Magnaldo T, St-Pierre Y. A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression[J]. Cancer Res,2005, 65 (12):5205-5210.
[94]Kennedy NJ, Davis RJ, Role of JNK in tumor development[J].Cell Cycle 2003,2(3):199-201.
[95]Suzuki T, Tsukamoto I. Manganese-induced apoptosis in hepatocytes after partial hepatectomy[J]. Eur J Pharmacol,2005,525(1-3):48-53.
[96]Kuwabara I, Kuwabara Y, Yang RY, et al. Galectin-7 (PIG1) exhibits proapoptotic function through JNK activation and mitochondrial cytochrome c release[J].J.Biol.Chem.2002,277(5):3487-3497.
[97]Matsui Y, Ueda S, Watanabe J, et al. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species[J]. Cancer Res.2007,67(3):1212-1220.
[1]Bruix,J.Sherman,M. Management of hepatocellular carcinoma[J]. Hepatology 2005,42(5):1208-1236.
[2]Llovet, J. M. Bruix, J. Novel advancements in the management of hepatocellular carcinoma[J]. J. Hepatol.2008,48(suppl.1), s20-s37.
[3]Parkin DM, Bray F,Ferlay J,et al.Global cancer statistics,2002 [J].CA Cancer J Clin,2005,55(2):74-108.
[4]中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作委员会,中华医学会肝癌学会肝病分会肝癌学组.原发性肝癌规范化诊治专家共识[J].临床肿瘤学杂志,2009,14(3)：259-269.
[5]Lopez PM, Villanueva A, Llovet JM. Systematic review:evidence-based management of hepatocellular carcinoma an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther,2006,23(11):1535-1547.
[6]Chow, P.K. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma:a multicenter randomized controlled trial[J]. Hepatology 2002,36(5): 1221-1226.
[7]Yuen M F.Poon RT.Lai ST. et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma[J]. Hepatology,2002,36(3):687-691.
[8]Becker, G., Allgaier, H. P, Olschewski, M., et al. Long-acting octreotide versus placebo for treatment of advanced HCC:a randomized controlled double-blind study[J]. Hepatology,2007,45(1):9-15.
[9]Llovet J M.Sale M. Castells L.et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma[J]. Hepatology,2000,31(1): 54-58.
[10]Yang T S, Lin Y C, Chen J S, et al. Phase ii study of gemcitabine in patients with advanced hepatocellular carcinoma[J]. Cancer,2000,89(4):750-756.
[11]Kubicka, s., rudolph, K. L., Tietze, M. K., et al Phase ii study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas[J]. Hepatogastroenterology.2001,48(39):783-789.
[12]Palmieri, G., Biondi, e., Morabito, A., et al. Thymostimulin treatment of hepatocellular carcinoma in liver cirrhosis[J]. Int. J. Oncol.1996,8(6):827-832.
[13]Stefanini G F. Foschi F G, Castelli E.et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients:a preliminary experience[J]. Hepatogastroenterology,1998,45(19):209-215.
[14]Kawata S.Yamasaki E. Nagase T.et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial[J]. Br. J. Cancer,2001,84(7):886-891.
[15]Hsu C. Chen CN, Chen LT. et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma[J]. Oncology,2003,65(3):242-249.
[16]Villa E. Ferretti I.Grottola A. et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors[J].Br.J.Cancer,2001,84(7):881-885.
[17]Kern M A.Schoneweiss MM. Sahi D.et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice[J]. Carcinogenesis,2004,25(7):1193-1199.
[18]Wada A.Fukui K. Sawai Y.et al. Pamidronate induced antiproliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma[J]. J. Hepatol,2006,44(1): 142-150.
[19]Zhu, A. X. systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? [J] Oncologist 2006,11(7):790-800.
[20]Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival[J]. Hepatology 2003,37(2):429-442.
[21]周信达.肝癌复发转移的研究进展[J].世界华人消化杂志.1999,7(3)：260-261.
[22]聂永梅,杨洁,罗超权,杨英洁,伍新尧.肝癌细胞膜受体含pRSVB7特异性配基的构建[J].世界华人消化杂志.2000,8(1)：63-66.
[23]Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus[J]. Ann Intern Med,2003,138(4):299-306.
[24]Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial[J]. Lancet,2000,356(9232):802-807.
[25]Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors[J]. J Clin Oncol,2004,22(8):1389-1397.
[26]Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas [J]. J Clin Oncol,2005,23(5): 999-1010.
[27]Schueller G, Stift A, Friedl J, et al. Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent to co-culture with tumor lysate pulsed dendritic cells[J].Int J Oncol,2003,22(6):1397-1402.
[28]Palmer DH, Midgley RS, Mirza N, et al A phase Ⅱ study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma[J]. Hepatology,2009,49(1):124-132.
[29]Kuang M, Peng BG, Lu MD, et al.Phase Ⅱ randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma [J]. Clin Cancer Res,2004,10(5):1574-1579.
[30]Geissler M, Mohr L, Dohler G, et al. Immunotherapy directed against alpha— fetoprotein results in autoimmune liver disease during liver regeneration in mice[J]. Gastroenterology,2001,121(4):931-939.
[31]Butterfield LH, Ribas A,Meng WS, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer [J]. Clin Cancer Res,2003,9(16):5902-5908.
[32]Butterfield LH, Ribas A, Dissette VB, et al. A phase Ⅰ/Ⅱ trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides [J]. Clin Cancer Res,2006,12(9): 2817-2825.
[33]汤勇,周训平,王晓芹.原发性肝癌的基因治疗进展[J].局解手术学杂志,2009,18(3)：202-203.
[34]Jicai Z, Zongtao Y, Jun L, et al. Persistent infection of hepatitis B virus is involved in high rate of p16 methylation in hepatocellular carcinoma[J].Mol Carcinog,2006,45(7):530-536.
[35]Zhang YJ, Rossner P Jr, Chen Y, et al.Aflatoxin B1 and polyc-yclic aromatic hydrocarbon adducts,p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients[J].Int J Cancer,2006,119(5): 985-991.
[36]穆红,王玉亮,刘蓉.野生型p53基因在人肝癌细胞的表达及诱导其凋亡[J].细胞与分子免疫学杂志,2006,22(6)：758-759.
[37]Huang JZ, Shen WI, Ii B, et al.Molecular and immunohisto-chemical study of theinactivation of the p16 gene in prima ryhepatocellular carcinoma[J]. Chin Med J,2000,113(9):889-893.
[38]Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy [J]. Gene Ther,2002,9(3):168-175.
[39]Won YS, Lee SW. Targeted retardation of hepatocarcinoma cells by specific replacement of alpha-fetoprotein RNA [J]. J B iotechnol,2007,129(4):614-619.
[40]Harada Y, Iwai M, Tanaka S, et al. Highly efficient suicide gene expression in hepatocellular carcinoma cells by epstein-barr virus-based plasmid vectors combined with polyamidoamine dendrimer [J].Cancer Gene Ther,2000, 7(1):27-36.
[41]Wang XW, Yuan JH, Zhang RG, et al. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonuc-leotides in vitro and in mice[J]. World J Gastroenterol,2001,7(3):345-351.
[42]Sun Y, Lin R, Dai J, et al. Suppression of tumor growth using antisense oligonucleotide against survivin in an orthotopic transplant model of human hepatocellular carcinoma in nudemice[J]. Oligonucleotides,2006,16(4): 365-374.
[43]Gu S, Liu CJ, Qiao T, et al. Inhibitory effect of antisense vascular endothelial growth factor 165 eukaryotic expression vector on proliferation of hepatocellular carcinoma cells[J].World J Gastroenterol.2004,10(4):535-539.
[44]李华,王欣璐,杨扬等RNAi靶向人端粒酶逆转录酶对人肝癌细胞的生长抑制作用[J].南方医科大学学报,2008,28(8)：1323-1326.
[45]Krause, D. s.& van etten, r. A. Tyrosine kinases as targets for cancer therapy [J]. N. Engl. J. Med.2005,353(2):172-187.
[46]Llovet JM, Bruix J.Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology.2008,48(4):1312-1327.
[47]Roberts LR. Sorafenib in liver cancer—just the beginning[J]. N Engl J Med 2008;359(4):420-422.
[48]Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J]. Cancer Chemother Pharmacol.2007,59 (5):561-574.
[49]Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med.2008,359(4):378-390.
[50]Goodman VL,Rock EP,Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma[J]. Clin Cancer Res,2007,13(5):1367-1337.
[51]Faivre SJ,Raymond E, Douillard J, et al. A ssessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC)[J]. Pro Am Soc Clin Oncol,2007, abstr 3546.
[52]Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts)with advanced hepatocellular carcinoma(HCC): Preliminary results of a phase Ⅱ study with circulating endothelial cell (CEC) monitoring [J]. Journal of Clinical Oncology,2007,25(18Suppl):4570.
[53]ZHU A X, BLASZKOW SKY L S, RYAN D P, et al. Phase Ⅱ study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma [J]. J Clin Oncol,2006,24(12):1898-1903.
[54]Hsu C,Cheng JC, Cheng AL, et al.Recent advances in non-surgical treatment for advanced hepatocellular carcinoma[J]. J FormosMed Assoc, 2004,103(7):483-495.
[55]Fazio N, Petralia G, Mancuso P, et al. Thalidomide in patients with advanced hepatocellular carcinoma: A clinical/biological study[J].Journal of Clinical Oncology,2007,25(18Suppl):15076.
[56]Chuah B, Lira R, Boyer M, et al. Multi-centre phase Ⅱ trial of thalidomide in the treatment of unresectable hepatocellular careinoma [J]. Acta Oncol,2007,46(2): 234-238.
[57]Schwartz JD, Sung M, Schwartz M,et al.Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha-a upon progression[J]. Oncologist,2005,10(9):718-727.
[58]Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor singnaling in human hepatocellular carcinoma [J]. Oncogene,2006,25(27): 3787-3800.
[59]O' Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group' s Study E1203[J]. Journal of Clinical Oncology,2006, 24(18Suppl):4143.
[60]Thomas MB, Chadha R, Glover K. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma [J]. Cancer,2007,110(5):1059-1067.
[61]Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma [J]. Cancer,2007,110(3):581-589.
[62]吴孟超.中医药在HCC防治中的作用、地位和存在的问题[J].中西医结合学报,2003,1(3)：163-164.
[63]陈洪,秦叔逵,陈惠英等.三氧化二砷抗肝癌作用的实验研究[J].中华肝脏病杂志,2000,8(1)：27-29.
[64]刘健,高建辉,刘晓秋.斑蝥素及其衍生物的研究进展[J].中药材,2003,26(6)：453-455.
[65]丰俊东,徐晓玉.川芎嗪含药血清对人肝癌细胞Bel-7402增殖的抑制作用[J].中草药,2005,36(4)：551-553.
[66]Deng X,Yin F,Lu X, et al.The apoptotic effect of brucine from the seed of Strychnos nux-vomica on human hepatoma cells is mediated via Bcl-2 and Ca2+ involved mitochondrial pathway[J].Toxicol Sci,2006,91(1):59-69.
[67]Deng X K,Yin W, Li W D,et al. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on Bel-7402 cells and its possible mechanism [J].J Ethnopharmacol,2006,106(2):179-186.
[68]Wang Q F,Chiang C W,Wu C C,et al.Gypenosides induce apoptosis in human hepatoma Huh27 cells through a calcium/reactive oxygen species-dependent m itochondrial pathway[J].Planta Med,2007,73(6):535-544.
[69]张晨,李柏,吕书勤等.蜂毒素对人肝癌细胞线粒体膜蛋白7A6和凋亡相关基因产物Fsa及其配体FasL表达的影响[J].中西医结合学报,2007,5(5)：559-562.
[70]朱青,张王刚,王立锋等.白藜芦醇诱导肿瘤细胞凋亡和细胞周期阻滞的作用及机制[J].第四军医大学学报,2005,26(21)：1935-1937.
[71]Liu T Z,Cheng J T,Yiin S J,et al.Isoobtusilactone a induces both caspase-dependent and-independent apoptosis in Bel-7402 cells [J]. Food Chem Toxicol,2008,46(1):321-327.
[72]Sa F, Gao J L,Fung K P,et al. Anti-proliferative and pro-apoptotic effect of Smilax glabra Roxb extract on hepatoma cell lines [J]. Chem Biol Interact,2008, 171(1):1-14.
[73]Hsu Y L, Kuo P L, Tzeng T F, et al. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo[J].J Gastroenterol Hepatol.2008,23(7 Pt2):290-299.
[74]Chan J Y, Tang P M, Hon P M, et al.Pheophorbidea, a major antitumor component purified from Scutellaria barbata,induces apoptosis in human hepatocellular carcinoma cells [J].Planta Med,2006,72(1):28-33.
[75]刘细平,陈宏伟,钟德玝.蜈蚣提取液对肝癌Bel-7404细胞体外抗癌作用的研究[J].现代中西医结合杂志,2009,18(32)：3935-3938.
[76]WuX Z, Chen D,Xie G R. Effects of Gekko sulfated polysaccharides on the proliferation and differentiation of hepatic cancer cell line[J]. Cell Biol Int,2006, 30(8):659-664.
[77]刘平,周建锋,胡义扬等.益气养阴诱导SMMC-7721肝癌细胞分化作用与意义[J].中国中医基础医学杂志,2000,6(8)：29-34.
[78]孟志强,于尔辛,宋明志等.健脾理气中药对肝癌端粒酶活性的影响[J].中国中医基础医学杂志,2000,6(1)：23-26.
[79]陈规划,张俊峰,陆敏强等.冬凌草甲素诱导肝癌细胞凋亡中Bcl-2及端粒酶变化的研究[J].中国中药杂志,2006,31(21)：1811-1814.
[80]张振宇,张赤志,许汉林等.皂荚提取物对人肝癌细胞相关癌基因表达的调控作用及端粒酶的影响[J].中西医结合肝病杂志,2008,18(2)：93-95.
[81]楼芳,秦叔逵,陈惠英.三氧化二砷对人类肝癌细胞株端粒酶活性的影响[J].临床肿瘤学杂志,2006,11(4)：250-253.
[82]朱灵,韦晓谋,杨春旭.蝎毒对人肝癌细胞Bel-7404凋亡及端粒酶逆转录酶基因的作用[J].广西医学,2008,30(2)：158-160.
[83]王新杰,郭勇义.益气健脾冲剂对转移性肝癌造模大鼠的影响[J].中医研究,2006,19(8)：11-13.
[84]Liu S,Yu M, He Y, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Racl-dependent pathway[J]. Hepatology, 2008,47(6):1964-1973.
[85]华海清,孙小昆,秦叔逵等.人参皂苷Rg3抗人肝癌细胞株侵袭和转移的实验研究[J].中国癌症杂志,2005,15(4)：326-330.
[86]韩盈,杨长春.活血化瘀药物对肝癌细胞Bel-7402的抑制作用及机制[J].解放军药学学报,2006,22(6)：401-404.
[87]丰俊东,徐晓玉.川芎嗪含药血清对人肝癌细胞Bel-7402增殖的抑制作用[J].中草药,2005,36(4)：551-553.
[88]郑国灿,李智英.丹参酮Ⅰ抗肿瘤作用及作用机制的实验研究[J].实用肿瘤杂志,2005,20(1)：33-35.
[89]丁罡,宋明志,于尔辛等.丹参、赤芍对大鼠Walker256癌肝转移影响机制的研究[J].中国癌症杂志,2001,11(4)：364-366.
[90]刘明章,黄贻穗,肖伟琪等.丹参酮ⅡA磺酸钠对Lewis癌无促进生长与转移 作用[J].中国药理学报,1991,12(6)：534-536.
[91]Zhu X F,Xie B F,Zhou J M, et al. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-Ⅲ (2',4'-dihydroxy-6-methoxy-3',5'-dimethylchal-cone), a component from Chinese herbal medicine [J].Mol Pharmacol,2005,67 (5):1444-1450.
[92]施京红,刘德传,吴仕九等.清香散对湿热型肝癌模型大鼠细胞凋亡、肿瘤血管生成的影响[J].陕西中医,2004,25(1)：84-86.
[93]华海清,秦叔逵,王锦鸿等.三氧化二砷抗肿瘤血管形成研究[J].世界华人消化杂志,2004,12(1)：27-31.
[94]何芳,曾文铤,朱科伦.人参皂苷Rg3抑制肝癌移植新生血管形成的研究[J].河南科技大学学报：医学版,2005,23(4)：245-247.
[95]王谦,张玲,毛海婷等.中药淫羊藿苷抑制肝癌Bel-7402.细胞增殖和免疫逃逸作用研究[J].中国免疫学杂志,2007,23：908-911.
[96]胡玲,王洪琦,崔娜娟等.白花蛇舌草对小鼠活体腹水H22肝癌细胞及T细胞的影响[J].广州中医药大学学报,2007,24(4)：313-316.
[97]吴英德,刘宗河,康平等.复方金蒲片治疗肝癌对铜、锌、硒元素水平及免疫功能影响的观察[J].广西医学,2006,28(11)：1692-1693.
[98]Thomas H, Coley H M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycop rotein [J]. Cancer Control,2003, 10(2):159-165.
[99]李起,刘作金,张俊等.中药复方肝癌-1号逆转肝癌多药耐药的实验研究[J].消化外科,2006,5(1)：70-73.
[100]梅英,石毓君,左国庆.川芎嗪逆转细胞肝癌细胞株Bel-7402/ADM多药耐药性的体外研究[J].中国中药杂志,2004,10(29)：970-973.
[101]朱建强,韩晓红,薛延军.中药柴胡提取物对人肝癌Bel-7402细胞内游离钙离子浓度和细胞内VCR蓄积的影响[J].北华大学学报,2005,6(1)：62-64.